BigOmics
BigOmics Analytics operates Omics Playground, a cloud-based, no-code analytics platform for biologists, bioinformaticians, and pharma R&D teams to perform interactive RNA-Seq, proteomics, and multi-omics data analysis, sold via SaaS subscriptions to biotech, pharmaceutical, and academic customers.
- Company typePrivate
- Founded2021
- HeadquartersBellinzona, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What BigOmics does
BigOmics Analytics SA is a Swiss cloud-software company that operates the Omics Playground, a self-service data analytics platform for the life sciences. The platform enables biologists, bioinformaticians, and R&D managers in biotech, pharmaceutical, and academic settings to perform interactive RNA-Seq and proteomics analyses — including clustering, differential expression, enrichment, biomarker discovery, drug connectivity, and protein network analysis — without writing code. Built primarily on R Shiny and delivered as a cloud web application, the platform ships 18+ analysis modules and 150+ interactive plots, and is differentiated by built-in co-analysis against 6,000+ public GEO datasets, a 50,000+ gene-set/pathway library, and 30,000+ drug expression profiles. A beta Multi-Omics add-on extends the core product into integrated epigenomics, transcriptomics, proteomics, and metabolomics workflows via SNF, MOFA, DIABLO, and MCIA.
The company sells through a hybrid go-to-market combining a product-led self-serve free trial (up to two years at auth.bigomics.ch) with a sales-led enterprise motion (request-a-demo funnel and dedicated Account Executive coverage of mid-market biotech accounts). Revenue is generated primarily through annual SaaS subscriptions executed via Order Forms, supplemented by training/onboarding services; pricing is quote-based rather than publicly listed. As of October 2025 the company reports 60+ biotech and pharma customers and institutes (including Merck, Sanofi, Vertex Pharmaceuticals, AbbVie, Parabilis Medicines, and Harvard Medical School) and a global researcher community of more than 6,000.
BigOmics is privately held and headquartered in Lugano, Switzerland, with co-founders Murat Akhmedov (CEO) and Ivo Kwee (CTO). The company has raised approximately $3.45M in disclosed venture funding across a December 2021 Pre-Series A, a March 2022 Eppendorf top-up, and an October 2025 round led by Diffusion Capital Partners alongside TiVentures and SICTIC business angels. Strategic partnerships with DNAnexus (proteomics/transcriptomics, 2023) and Almaden Genomics (end-to-end workflows, 2024) extend its ecosystem footprint.
BigOmics firmographics
Firmographics- Name
- BigOmics
- Legal name
- BigOmics Analytics SA
- Website
- https://bigomics.ch
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BigOmics Analytics operates Omics Playground, a cloud-based, no-code analytics platform for biologists, bioinformaticians, and pharma R&D teams to perform interactive RNA-Seq, proteomics, and multi-omics data analysis, sold via SaaS subscriptions to biotech, pharmaceutical, and academic customers.
- Ownership category
- akta.pro rank
BigOmics industry classification
Industry- Product category
- Bioinformatics Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
- akta.pro secondary industries
- Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where BigOmics is headquartered
LocationHeadquarters
- HQ city
- Bellinzona
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
BigOmics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
Revenue model
- Omics Playground subscription (SaaS): Customer purchases subscriptions and access to the Services by executing one or more Order Forms. Fees are non-refundable, exclude VAT, payable within 30 days by wire transfer. Order Forms auto-renew for successive Renewal Terms unless either party gives 90 days notice; BigOmics may raise Fees for Renewal Terms with 90 days notice.
- Free trial / freemium tier: Free trial offered to enable evaluation prior to a paid plan, with a maximum trial duration of two years. BigOmics reserves the right to modify conditions including feature access, dataset limits, storage capacity and trial duration. Cancelled or non-renewed paid accounts may be automatically downgraded to a free trial plan.
- Training, onboarding, and support services: Training, onboarding, and support services provided as specified on Order Forms; customer pays agreed travel expenses in addition to fees.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Pay-as-you-go | Free trial plan (up to 2 years, evaluation only) |
| Subscription | Annual | Paid subscription (quote-based via Order Form) |
Go-to-market motion4 records
Distribution channels3 records
Marketing channels8 records
BigOmics product offering
Product offeringCore offering
BigOmics Analytics provides a cloud-based, self-service omics data analysis platform (Omics Playground) for biologists, bioinformaticians, and pharma/biotech research teams. The platform delivers interactive visualization and analysis of RNA-Seq, proteomics, and multi-omics data via 18+ analysis modules and 150+ interactive plots, with built-in access to 6,000+ public datasets, 50,000+ gene sets and pathways, and 30,000+ drug expression profiles. An add-on Multi-Omics Playground extends the platform with SNF, MOFA, DIABLO, and MCIA integration methods for multi-layer omics analysis, biomarker discovery, and drug repurposing workflows.
Product overview
BigOmics Analytics offers a single unified cloud-based platform, Omics Playground, for interactive omics data analysis, with an add-on module (Multi-Omics Playground) for multi-omics integration and two primary analysis workflows (RNA-Seq Data Analysis and Proteomics Data Analysis) layered on top. The core Omics Playground provides 18+ analysis modules and 150+ interactive plots for biologists, bioinformaticians, and managers, with co-analysis against 6,000+ public datasets and 50,000+ gene sets. The Multi-Omics add-on (in beta) extends the platform with SNF, MOFA, DIABLO, and MCIA integration methods to harmonize transcriptomics, proteomics, epigenomics, and metabolomics data. The platform is positioned as a complete self-service analytics solution for biotech, pharma, and academic labs, also packaged as a Drug Discovery Solution for pharmaceutical R&D.
Differentiator
Problem solved
Functional benefit
Brands
- Omics Playground: Cloud-based, self-service omics data analysis platform for interactive visualization and analysis of RNA-Seq, proteomics, and multi-omics data; includes 18+ analysis modules, 150+ interactive plots, co-analysis with 6000+ public datasets, 50,000+ public gene sets and pathways, and drug connectivity databases.
- Multi-Omics Playground
Products and services
- Omics Playground Cloud-based, interactive omics data analysis platform that enables biologists and bioinformaticians to explore, visualize, and interpret RNA-Seq and proteomics data without coding. Provides 18+ analysis modules, 150+ interactive plots, co-analysis with 6,000+ public datasets, and 50,000+ gene sets/pathways for biomarker analysis, drug connectivity, enrichment/pathway analysis, WGCNA and PCSF network analysis, and clustering/differential expression tools.
- Multi-Omics Playground Beta add-on module that extends Omics Playground with multi-omics data integration across epigenomics, transcriptomics, proteomics, and metabolomics. Uses state-of-the-art integration methods including SNF (Similarity Network Fusion), MOFA (Multi-Omics Factor Analysis), DIABLO (supervised integration), and MCIA (Multiple Co-Inertia Analysis) for code-free multi-omics analysis workflows.
- RNA-Seq Data Analysis Specialized workflow within Omics Playground for RNA-Seq data analysis, supporting differential expression analysis, gene set enrichment, pathway analysis, and biomarker identification from bulk and single-cell RNA-seq data.
- Proteomics Data Analysis Specialized workflow within Omics Playground for proteomics data analysis, including abundance table ingestion, missing value imputation (e.g., SVDimpute), normalization (e.g., maxMedian), differential protein expression, PSEA, pathway analysis (WikiPathways, Reactome), biomarker identification, drug connectivity, WGCNA and PCSF network analysis. Supports Olink Target proteomics data formats.
- Omics Playground for Drug Discovery Solution-oriented offering of Omics Playground configured as a drug discovery solution for pharmaceutical R&D, leveraging biomarker analysis, drug connectivity databases with 30,000+ drug expression profiles, drug sensitivity databases, drug modes of action analysis, and repurposable drug identification.
Quantifiable outcome
- 75% increase in collaboration effectiveness
- +6 more outcomes
Companies that use BigOmics
Customer profileNamed customers19 records
Segments5 records
Ideal customer profiles4 records
BigOmics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability7 records
Feature10 records
BigOmics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered major, core and minor.
- Almaden GenomicsmajorAnnounced February 22, 2024: BigOmics and Almaden Genomics collaborated to provide end-to-end omics data analysis. Partnership spans co-authored case studies (e.g., IL-17A / osteoarthritis RNA-Seq use case) combining Almaden's reagent/sample prep with BigOmics' analysis platform.
- DNAnexuscoreAnnounced August 2, 2023: DNAnexus and BigOmics Analytics partnered to improve proteomics and transcriptomics data visualization and interpretation. The integration delivers a complete collaborative environment with an intuitive interface addressing common analysis bottlenecks across the two platforms.
- Swiss Biotech AssociationminorBigOmics is a member of the Swiss Biotech Association (swissbiotech.org); member logo displayed in homepage footer.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
BigOmics competitors and assessment
Company assessmentDirect peers
- DNAnexus: Cloud-based genomics and biomedical data analysis platform serving pharma, clinical, and academic customers. Direct peer — DNAnexus is both BigOmics' Aug 2023 integration partner and a broader cloud-bioinformatics competitor offering overlapping omics analysis and visualization.
- Genedata: Enterprise bioinformatics platform for pharma R&D, including omics data analysis, screening, and biopharma workflow automation. Direct peer serving the same biotech/pharma buyer with code-free analytical workflows similar in spirit to Omics Playground.
- Partek: Genomics and multi-omics analysis software (Partek Flow, Partek Genomics Suite) used by biologists and bioinformaticians for RNA-Seq, single-cell, and multi-omics workflows. Direct peer in code-assisted omics analytics targeting overlapping academic and pharma buyer personas.
- Seven Bridges (Velsera): Cloud bioinformatics platform for NGS, multi-omics, and biomedical data analysis serving pharma, research consortia, and clinical customers. Direct peer offering code-free and programmatic omics workflows over large public reference datasets similar to BigOmics' co-analysis library.
Broad incumbents
- QIAGEN Digital Insights (QIAGEN Bioinformatics / OmicSoft): Broad incumbent in omics data analysis and interpretation, including OmicSoft and Ingenuity Pathway Analysis, serving pharma, academic, and clinical customers. Larger, more established alternative to BigOmics with deeper pharma footprint and a much broader product portfolio.
- Dotmatics: Scientific R&D informatics platform spanning biology, chemistry, and lab data, including omics and biomarker workflows. Broad incumbent offering overlapping omics analytics capabilities as part of a much wider scientific data platform aimed at enterprise pharma.
- Illumina (Illumina Connected Analytics / BaseSpace): Sequencing-instrument incumbent that also offers cloud bioinformatics (BaseSpace, Illumina Connected Analytics) for secondary and tertiary omics analysis. Broad incumbent with significant reach into BigOmics' academic and pharma customer base via installed sequencer footprints.
Emerging players
- Pluto Bio: Cloud-based omics analytics platform targeting biologists in pharma and biotech with no-code analysis of RNA-Seq, proteomics, and other omics data. Emerging player with a similar no-code, biologist-friendly thesis and a smaller, more focused product surface than BigOmics.
- Rosalind (Tempus): Cloud-based, code-free omics analysis platform originally targeted at academic and translational researchers, now part of Tempus AI. Emerging peer with a similar PLG, code-free analytical approach and overlapping biological user persona.
Others
- Olink (now part of Thermo Fisher Scientific): Proteomics platform using Proximity Extension Assay technology, which BigOmics' Omics Playground directly supports as an analysis workflow (Aug 2025 tutorial). Adjacent ecosystem participant — BigOmics ingests and analyses Olink data, making Olink a strategic ecosystem partner rather than a direct competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
BigOmics social profiles
Digital presenceBigOmics financial estimates
Financial estimateRevenue estimate
Valuation estimate
BigOmics leadership team
Management profileNumber of profiles
Profiles3 records
BigOmics funding detail
Funding detailFunding overview
Funding rounds6 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BigOmics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BigOmics
What does BigOmics do?
BigOmics Analytics provides a cloud-based, self-service omics data analysis platform (Omics Playground) for biologists, bioinformaticians, and pharma/biotech research teams. The platform delivers interactive visualization and analysis of RNA-Seq, proteomics, and multi-omics data via 18+ analysis modules and 150+ interactive plots, with built-in access to 6,000+ public datasets, 50,000+ gene sets and pathways, and 30,000+ drug expression profiles. An add-on Multi-Omics Playground extends the platform with SNF, MOFA, DIABLO, and MCIA integration methods for multi-layer omics analysis, biomarker discovery, and drug repurposing workflows.
Is BigOmics a public or private company?
BigOmics is a private company. It is classified as venture growth investor backed and is currently operating.
When was BigOmics founded?
BigOmics was founded in 2021. It employs 11 to 50 people.
Where is BigOmics based?
BigOmics is headquartered in Bellinzona, Switzerland, in the Europe region.
How does BigOmics make money?
Three revenue lines are on record. Omics Playground subscription (SaaS) is the primary driver. The others are free trial / freemium tier and training, onboarding, and support services.
Who are BigOmics's main competitors?
Direct peers on record are DNAnexus, Genedata, Partek and Seven Bridges (Velsera). Broad incumbents are QIAGEN Digital Insights (QIAGEN Bioinformatics / OmicSoft), Dotmatics and Illumina (Illumina Connected Analytics / BaseSpace). Emerging players are Pluto Bio and Rosalind (Tempus). Olink (now part of Thermo Fisher Scientific) is listed as an others.
Does BigOmics have an API?
No public API is recorded for BigOmics.
What industry is BigOmics in?
BigOmics's product category is Bioinformatics Software. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics). Its NAICS code is 541714 and its SIC code is 8731.